Team tests power of focused ultrasound, immunotherapy to battle breast cancer

November 8, 2017, University of Virginia

In its latest pioneering effort to harness the power of focused ultrasound to battle disease, the University of Virginia Health System is examining the scalpel-free surgery's potential to enable the body to identify and destroy metastatic breast cancer cells.

Researchers Patrick Dillon, MD, and David Brenin, MD, of the UVA Cancer Center, have launched a clinical trial evaluating the safety and effectiveness of a two-pronged experimental approach to combatting that has spread to other parts of the body. The researchers use focused ultrasound to destroy a portion of the primary tumor, with the goal of prompting an immune response. Study participants receive the immunotherapy drug pembrolizumab in the hopes it will prevent the cells from blocking that immune response. This may allow the patient's immune system to recognize and kill the cancer cells.

"The hope," Brenin said, "is to leverage the combination of both treatments to gain a greater than we would have individually."

Targeting Breast Cancer Cells

Previous studies have suggested that focused ultrasound, on its own, initiates an immune reaction inside the body, Dillon explained. The trial is essentially using it to flag up the - which are normally invisible to the immune system - so that the body's can recognize them as a danger.

The trial is believed the first to pair focused ultrasound with immunotherapy, Dillon noted. "We are looking at the safety and feasibility [of the combination], and also looking to see if we receive a response beyond the treated tumor in the breast," he said.

The researchers plan to test the combo in a total of 15 women, ages 18 and older, who have received at least one form of treatment for their metastatic cancer. There are other eligibility requirements as well. Participants will be randomized to receive the drug, known commercially as Keytruda, either before or after the focused . (Keytruda is not approved for the treatment of breast cancer - it's considered experimental for the purposes of the trial.)

The researchers expect it will take a year to 14 months to complete their testing. They will then evaluate their results and publish their findings in a scientific journal. If their initial test is successful, a larger trial would be conducted to further evaluate the safety and effectiveness of the procedure.

The trial is the latest in UVA's efforts to explore the potential of focused ultrasound. UVA's Jeff Elias, MD, pioneered the use of the technology for the treatment of essential tremor, the most common movement disorder, and the Food and Drug Administration has since approved focused ultrasound for that purpose. At the end of October, Elias unveiled the results of a small initial trial examining its potential for managing tremor caused by tremor-dominant Parkinson's disease. That study concluded a larger trial is warranted. Other researchers are evaluating the technology for additional applications as well.

"The most exciting part of our job," Dillon said, "is to be able to participate in research that will impact patient lives and potentially alter their cancer journey in, hopefully, a positive way."

About Focused Ultrasound

The technology focuses sound waves inside the body to create a small but concentrated spot of heat, much like a magnifying glass can focus sunlight. Doctors can use that heat to destroy unwanted tissue in a process called "ablation." Unlike traditional surgery, there is no need to cut into the body.

Explore further: Focused ultrasound shows promise for treating Parkinson's tremor

Related Stories

Focused ultrasound shows promise for treating Parkinson's tremor

October 30, 2017
An initial test to determine if a scalpel-free form of brain surgery can reduce tremor caused by Parkinson's disease has produced encouraging results. Further research is warranted, the researchers conclude in a paper published ...

Focused ultrasound named one of 2016's top clinical research achievements

April 19, 2017
The University of Virginia Health System's pioneering use of focused sound waves to treat essential tremor, the most common movement disorder, has been named one of the top 10 clinical research achievements of 2016.

Focused ultrasound for treating Parkinson's disease to be tested

October 12, 2012
(Medical Xpress)—After a promising clinical trial of focused ultrasound as a potential treatment for essential tremor, the University of Virginia Health System is launching a new study to investigate the scalpel-free technology's ...

FDA approves scalpel-free brain surgery for tremor pioneered at UVA

July 12, 2016
The Food and Drug Administration has approved the first focused-ultrasound device to treat essential tremor, the most common movement disorder, in patients who do not respond to medication. The scalpel-free approach has been ...

Molecular fingerprint of breast tumors linked to immune response in bloodstream

September 28, 2017
Using newly developed software, researchers have shown that genes and molecular processes in breast cancer tumor cells are tightly linked to genes and processes in blood cells, including immune system cells. The findings ...

New ultrasound technology could save lives of women with dense breast tissue

September 1, 2017
A new research project at the USC Norris Comprehensive Cancer Center is recruiting women with dense breast tissue to examine the effectiveness of a novel breast ultrasound device. SoftVue is the world's first 3-D, whole-breast ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.